This study is completed in France, in Argentina, in Egypt, .... It is testing olanzapine for schizophrenia.
SchizophreniaDrugFrom 18 Years to 65 Years
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Then choose your country and confirm availability with each study site.
In plain English
Key information made simple
What is this study testing?
This study is testing whether olanzapine may be useful for adults experiencing schizophrenia.
What would participation involve?
Participants may receive olanzapine, attend study visits with the research team. The protocol may also involve randomization, placebo, or a comparison group. The registry lists locations in Argentina, in Egypt, and in Estonia.
Who is it mainly for?
This study appears to be mainly for adults with schizophrenia.
What should you check before joining?
Ask about the dose, safety monitoring, and possible side effects, whether there is placebo, randomization, or a comparison group, how many visits or travel steps are needed, the exact eligibility criteria.
Your next step
Check the study details
Check the official source, then confirm these points with the research team.
Where are visits, can any be remote, and how much time is needed?
Costs and support
What costs, reimbursement or compensation apply?
Before joining
Questions to ask before joining
What are the exact eligibility criteria, and what could exclude someone?
How many visits, assessments, or follow-ups are expected, and over what period?
What risks, side effects, practical burdens, or alternatives should be understood first?
Who should be contacted to confirm locations, timing, compensation, and next steps?
Study clarity
Things to check before joining
Study start dateOctober 2007
Recruitment status
Completed
Enrollment listed in the registry
462
Sponsor
Janssen-Cilag International NV
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Locations
France, Argentina, Egypt, ...
Age range
From 18 Years to 65 Years
Official registry ID
NCT00645099
Official title
A Prospective Randomized Open-label 6-Month Head-To-Head Trial to Compare Metabolic Effects of Paliperidone ER and Olanzapine in Subjects With Schizophrenia
Check recruitment and locations
Recruitment checked against the registry by HopeStage on . Registry information can change. Always confirm availability with the research team.
The overall study status can differ from each site's status. Open a country to see its locations and their registry status.
Argentina · 3 sites
Buenos Aires
Buenos Aires
Site status: Not listed — confirm with the team
Córdoba
Córdoba
Site status: Not listed — confirm with the team
Mendoza
Mendoza
Site status: Not listed — confirm with the team
Egypt · 3 sites
Alexandria
Alexandria
Site status: Not listed — confirm with the team
Cairo
Cairo
Site status: Not listed — confirm with the team
El Banfaig 2 District
El Banfaig 2 District
Site status: Not listed — confirm with the team
Estonia · 3 sites
Pärnu
Pärnu
Site status: Not listed — confirm with the team
Tallinn
Tallinn
Site status: Not listed — confirm with the team
Tartu
Tartu
Site status: Not listed — confirm with the team
France · 5 sites
Allonnes
Allonnes
Site status: Not listed — confirm with the team
Bron
Bron
Site status: Not listed — confirm with the team
Dijon
Dijon
Site status: Not listed — confirm with the team
Limoges
Limoges
Site status: Not listed — confirm with the team
Montberon
Montberon
Site status: Not listed — confirm with the team
Greece · 1 site
Athens
Athens
Site status: Not listed — confirm with the team
Jordan · 1 site
Amman
Amman
Site status: Not listed — confirm with the team
Latvia · 5 sites
Jelgava
Jelgava
Site status: Not listed — confirm with the team
Liepāja
Liepāja
Site status: Not listed — confirm with the team
Riga
Riga
Site status: Not listed — confirm with the team
Sigulda
Sigulda
Site status: Not listed — confirm with the team
Strenči
Strenči
Site status: Not listed — confirm with the team
Lebanon · 1 site
Beirut
Beirut
Site status: Not listed — confirm with the team
Lithuania · 2 sites
Kaunas
Kaunas
Site status: Not listed — confirm with the team
Vilnius
Vilnius
Site status: Not listed — confirm with the team
Romania · 5 sites
Cluj-Napoca
Cluj-Napoca
Site status: Not listed — confirm with the team
Craiova
Craiova
Site status: Not listed — confirm with the team
Oradea
Oradea
Site status: Not listed — confirm with the team
Sibiu
Sibiu
Site status: Not listed — confirm with the team
Tg Mures
Tg Mures
Site status: Not listed — confirm with the team
Slovakia · 3 sites
Bratislava
Bratislava
Site status: Not listed — confirm with the team
Michalovce
Michalovce
Site status: Not listed — confirm with the team
Rimavská Sobota
Rimavská Sobota
Site status: Not listed — confirm with the team
South Africa · 2 sites
Cape Town
Cape Town
Site status: Not listed — confirm with the team
Johannesburg
Johannesburg
Site status: Not listed — confirm with the team
Spain · 8 sites
A Coruña
A Coruña
Site status: Not listed — confirm with the team
Alicante
Alicante
Site status: Not listed — confirm with the team
Barcelona
Barcelona
Site status: Not listed — confirm with the team
Elche
Elche
Site status: Not listed — confirm with the team
Madrid
Madrid
Site status: Not listed — confirm with the team
Santander
Santander
Site status: Not listed — confirm with the team
Vic
Vic
Site status: Not listed — confirm with the team
Zamora
Zamora
Site status: Not listed — confirm with the team
Türkiye · 4 sites
Ankara
Ankara
Site status: Not listed — confirm with the team
Bursa
Bursa
Site status: Not listed — confirm with the team
Istanbul
Istanbul
Site status: Not listed — confirm with the team
Manisa
Manisa
Site status: Not listed — confirm with the team
Ask HopeStage to help me review this study
This record does not confirm open recruitment. We can help you understand it and explore other studies.
Study ID: NCT00645099. We help you review the study, but cannot decide medical eligibility.
In practice
For you
Participation may contribute to research. Personal benefit is not guaranteed.
Ask the research team to explain the activities, time commitment, and follow-up involved.
Study sites are listed. Confirm the relevant site and any travel before making plans.
Important
Not medical advice
Information from public sources.
Are you the study sponsor? Contact us to update this page: hi@hopestage.com
FAQ
Questions about this study
What is this study trying to understand?
This study is exploring medication or study treatment for people with schizophrenia. Participants may complete study visits, assessments, or follow-up activities defined by the research team. Direct benefit is not guaranteed. The detailed objective is not always clearly listed in the public registry; the study team can confirm.
Does this study involve a medication?
This appears to be a medication / drug study involving olanzapine, paliperidone ER. Phase 3 studies are usually larger and aim to confirm effectiveness and safety in a broader group.
Who might this study be for?
This study may concern people with schizophrenia; age range: From 18 Years to 65 Years. The criteria appear fairly broad, but you should not assume you are eligible. The study team must confirm diagnosis, age, exclusions, available locations, and next steps.
What would I likely need to do?
You may need to take a study treatment and have regular medical follow-up. The listed study locations suggest that at least part of participation may involve a physical site. Ask whether some steps can be done remotely.
What side effects, interactions, or treatment changes should I check?
If the study involves a medication, ask whether it is already approved, experimental, or being tested for a new use. Check possible side effects, interactions with current treatment, dose changes, monitoring, and what happens if you feel worse. For any mental health study, also ask who to contact if you feel worse, whether participation may affect current treatment, whether you can stop, and who confirms eligibility.
Will I need to travel or attend in-person visits?
The listed study locations suggest that at least part of participation may involve a physical site. Ask which sites are open, how many visits are expected, whether any steps can be done remotely, and whether travel costs or compensation are listed.
Who is behind this study?
This study is sponsored by Janssen-Cilag International NV, which appears to be unknown or unclear. If available, it can be useful to check the sponsor website, collaborators, investigator affiliation, and the official registry before deciding. HopeStage does not judge the quality of a sponsor or researcher, but helps you identify what to verify.
Can I still join this study?
The public registry lists this study as not currently recruiting. This page remains available for information. Check the official record for the latest status and explore other recruiting studies.
Explore other studies
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.